What is Insitro?
Insitro operates as a data-driven drug discovery organization that leverages machine learning to decode the complexities of human biology. By synthesizing in vitro cellular data with clinical information, the company aims to accelerate the development of transformative medicines across critical therapeutic areas, including oncology, metabolism, and neuroscience. The firm's multidisciplinary team of engineers, data scientists, and life scientists works to redefine disease modeling, ultimately reducing the time and cost associated with bringing novel therapies to patients in need.
How much funding has Insitro raised?
Insitro has raised a total of $643M across 3 funding rounds:
Series A
$100M
Series B
$143M
Series C
$400M
Series A (2019): $100M with participation from ARCH VENTURE PARTNERS, GV, Foresite Capital, Bezos Expeditions, Mubadala, Third Rock Ventures, Two Sigma Ventures, and Verily
Series B (2020): $143M led by Casdin Capital, HOF Capital, BlackRock, WuXi AppTec, Andreessen Horowitz, T. Rowe Price Associates, and CPP Investments
Series C (2021): $400M supported by Andreessen Horowitz, T. Rowe Price Associates, Two Sigma Ventures, Alexandria Venture Investments, ARCH VENTURE PARTNERS, GV, HOF Capital, CPP Investments, BlackRock, Third Rock Ventures, Casdin Capital, and Foresite Capital
Key Investors in Insitro
Andreessen Horowitz
A prominent venture capital firm that invests in software-eating-the-world trends, providing significant capital and operational expertise to high-growth technology and biotech companies.
T. Rowe Price Associates
A global investment management firm that provides institutional-grade capital to support the long-term growth and scaling of innovative enterprises.
Two Sigma Ventures
An early-stage venture capital firm that specializes in companies leveraging data science, artificial intelligence, and advanced computing to drive industry-wide transformation.
What's next for Insitro?
With substantial financial backing, Insitro is well-positioned to scale its therapeutic pipeline and deepen its computational capabilities. The company's strategic focus remains on expanding its data-generation infrastructure and refining its predictive models to identify high-potential therapeutic targets. As the firm matures, the emphasis will likely shift toward advancing its internal programs into clinical trials, further validating its unique approach to drug development and potentially disrupting traditional pharmaceutical R&D paradigms.
See full Insitro company page
